Scientific Reports (Sep 2024)

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

  • Elisabeth Roider,
  • Alexandra I. T. Lakatos,
  • Alicia M. McConnell,
  • Poguang Wang,
  • Alina Mueller,
  • Akinori Kawakami,
  • Jennifer Tsoi,
  • Botond L. Szabolcs,
  • Anna A. Ascsillán,
  • Yusuke Suita,
  • Vivien Igras,
  • Jennifer A. Lo,
  • Jennifer J. Hsiao,
  • Rebecca Lapides,
  • Dorottya M. P. Pál,
  • Anna S. Lengyel,
  • Alexander Navarini,
  • Arimichi Okazaki,
  • Othon Iliopoulos,
  • István Németh,
  • Thomas G. Graeber,
  • Leonard Zon,
  • Roger W. Giese,
  • Lajos V. Kemeny,
  • David E. Fisher

DOI
https://doi.org/10.1038/s41598-024-72031-9
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Microphthalmia-associated transcription factor (MITF) is a master regulator of melanocyte function, development and plays a significant role in melanoma pathogenesis. MITF genomic amplification promotes melanoma development, and it can facilitate resistance to multiple therapies. Here, we show that MITF regulates a global antioxidant program that increases survival of melanoma cell lines by protecting the cells from reactive oxygen species (ROS)-induced damage. In addition, this redox program is correlated with MITF expression in human melanoma cell lines and patient-derived melanoma samples. Using a zebrafish melanoma model, we show that MITF decreases ROS-mediated DNA damage in vivo. Some of the MITF target genes involved, such as IDH1 and NNT, are regulated through direct MITF binding to canonical enhancer box (E-BOX) sequences proximal to their promoters. Utilizing functional experiments, we demonstrate the role of MITF and its target genes in reducing cytosolic and mitochondrial ROS. Collectively, our data identify MITF as a significant driver of the cellular antioxidant state.